8-K: America Great Health Subsidiary Enters Technology Contract for Cancer Cell Inhibiting Peptide Development

America Great Health's subsidiary, International Institute of Great Health, has secured a contract with Yunan Yunchi Xiai Trading Co. Ltd. to develop cancer cell inhibiting technology using its patented protein modification process.

Summary

• America Great Health's wholly-owned subsidiary, International Institute of Great Health, has entered into a Technology Contract with Yunan Yunchi Xiai Trading Co. Ltd.
• The contract involves the development of specialized technology for Yunchi's birds nest ionic peptide project.
• America Great Health will apply its patented protein skin surface ion modification technology to Yunchi's raw materials.
• This technology aims to preserve the original properties of the materials while adding the ability to inhibit the growth of cancer cells in vitro.
• The technology development will occur in a US laboratory, with the experimental base located in China.
• The development period is scheduled for two and a half months.

Sentiment

Score: 7

Explanation: The announcement is positive due to the new contract and potential for innovative technology, but there are risks associated with the development phase and international collaboration.

Positives

• The contract represents a new revenue stream for America Great Health through its subsidiary.
• The technology has the potential to create a valuable product with cancer-inhibiting properties.
• The project leverages the company's patented technology, showcasing its innovation capabilities.
• The development timeline is relatively short at 2.5 months.

Risks

• The project involves a Chinese company, which may introduce geopolitical and operational risks.
• The success of the technology in inhibiting cancer cells is based on in vitro testing, and may not translate to in vivo results.
• The project is in the development phase and may not lead to commercial success.

Future Outlook

The company will be focused on completing the technology development within the 2.5 month timeframe.

Management Comments

• Mike Wang, President of America Great Health, signed the report.

Industry Context

This announcement highlights the growing interest in using natural products and advanced technologies for health and wellness applications, particularly in cancer research.

Comparison to Industry Standards

• The use of protein modification technology for cancer cell inhibition is an area of active research, with companies like Amgen and Genentech exploring similar approaches.
• The 2.5 month development timeline is relatively short compared to typical pharmaceutical development timelines, which can take several years.
• The focus on birds nest raw materials is unique, as most cancer research focuses on more traditional sources of compounds.

Stakeholder Impact

• Shareholders may view this as a positive development due to the potential for new revenue and innovative technology.
• Employees involved in the project will be working on a potentially groundbreaking technology.
• Customers of Yunchi may benefit from the new cancer-inhibiting product.

Next Steps

• The company will commence the technology development in a US laboratory.
• The experimental base will be established in China.
• The company will aim to complete the development within 2.5 months.

Key Dates

Keywords

Technology Contract, Cancer Cell Inhibition, Protein Modification, Ionic Peptide, Birds Nest, International Institute of Great Health, Yunan Yunchi Xiai Trading Co. Ltd.